Several clinical trials of B and plasma cell directed therapies are demonstrating posi-tive results across a broad range of non-oncological, immune mediated diseases including systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes, multiple sclerosis, and Sjogren's syndrome. However, the vast potential of developing next generation B cell directed therapies remains challenging with limited fundamental knowledge on the role of B and plasma cell subtypes in health, autoimmunity and the wider immune system.
Our virtual summit arrives as the first ever cross-disciplinary meeting for large pharma, biotech and academia. This forum is dedicated to harnessing the full therapeutic opportunity of numerous candidates directed against various B and plasma cell targets (incl. CD20, PI3K, BTK and more). Come armed with questions, ideas and ex-periences and together, take steps to develop the next generation of B cell directed therapies to improve immune mediated disease management, define effective combination treatment regimens and transform patient outcomes.
Industry Pricing: USD 1799.0,
Standard Pricing: USD 2099.0,
Academic Pricing: USD 1499.0
Speakers: Aimee Payne, Professor and Co-Founder of Cabaletta BioUniversity of Pennsylvania, Paul Smith, Senior Director - Pharmacology (Non-Oncology), Incyte Corporation, Amit Choudhury, Principal Scientist: M267 CD38 SIFbody Program Co-Lead, Momenta Pharmaceuticals, Gregory Wu, Associate Professor of Neurology, Washington University in St. Louis, School of Medicine, Jessica Kenison-White, Senior Scientist, AnTolRx, Inc., Claire Langrish, Vice President - Immunology and Biology, Principia Biopharma, Thomas Tedder, Alter Geller Distinguished Professor for Research in Immunology, Duke University School of Medicine, Martin Kaul, Executive Director Translational Medicine, Autoimmunity, Novartis Institutes for Biomedical Research, Michael Mingueneau, Associate Director, Multiple Sclerosis Research Unit, Biogen, and more!
Time: 09:00 - 16:30